Celltrion Group has successfully sold the Asia-Pacific (APAC) “Primary Care” business rights, which it acquired from multinational pharmaceutical company Takeda Pharmaceuticals (hereafter Takeda) in 2020, after three years.On Jan. 18, Celltrion concluded a contract with Dong-A Pharmaceutical for the
Celltrion Group revealed on Jan. 2 that it plans to divest the business rights, excluding domestic specialty pharmaceuticals, of the Primary Care sector in the Asia-Pacific region that it acquired from multinational pharmaceutical company Takeda Pharmaceutical in 2020. This split sale, which exclude
South Korea, China, and Japan are accelerating the growth and development of their pharmaceutical and biotech industries. South Korea’s third five-year national plan to that end was announced on March 24 and China’s first long-term national plan in the sector was announced in May last year.Japan’s p
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Although the global bio sector index continues to be sluggish, we believe it will be important to pay close attention to global clinical trial data for ADC and KRAS inhibitors at 2022 ASCO (Jun 3~7).
The Federation of Korean Industries recently analyzed the top 10 sales companies in the United States, South Korea and Japan and announced on March 17 that the 10 South Korean companies signed 260 M&A deals for the past 10 years while the 10 Japanese and 10 U.S. companies signed 787 and 751 deals, r
GC LabCell said on March 15 that its subsidiary Artiva licensed out its CAR-NK technology to the multinational pharmaceutical company MSD for US$1.88 billion in January. This contract applies only to three types of solid cancers. This is the second largest license-out deal for NK technology. CAR-NK
Last year, the top 10 South Korean business groups signed 20 M&A deals despite COVID-19 in order to ensure their future growth. For instance, SK Hynix acquired Intel’s NAND flash business unit for 10.3 trillion won in October last year. Hyundai Motor Group signed two major deals, that is, Boston Dyn
The author is an analyst of KB Securities. She can be reached at kahye.hong@kbfg.com. -- Ed. Solid 3Q20 results Celltrion reported 3Q20 consolidated revenue/OP of KRW548.8bn (+28.0% QoQ/+89.9% YoY)/ 245.3bn (+34.9% QoQ/+137.8% YoY). Revenue was above our estimate/the market consensus by 15%/19%, wit
The author is an analyst of KB Securities. She can be reached at kahye.hong@kbfg.com. -- Ed. Initiate coverage with BUY and target price of KRW340,000 We initiate coverage of Celltrion with a BUY rating and TP of KRW340,000. Our DCF-derived TP (50.5x 2021 P/E) reflects 6.04% WACC (6.04% cost of equi
GC Pharma is accelerating the development of COVID-19 plasma treatment. In South Korea, the company initiated the second phase of its clinical trial with GC5131 on Sept. 21. The CoVIg-19 Plasma Alliance, whose members include GC Pharma, BPL, CSL, Takeda, Octapharma and Biotest, will initiate the thi
The authors are analysts of NH Investment & Securities. They can be reached at william.ku@nhqv.com and weihan@nhqv.com, respectively. – Ed. 1. US bio sector fared worse y-y in every aspect in 2019Average IPO value fallsIn 2019, the US bio sector fared worse compared to 2018 in every aspect. The numb
GC Pharma announced on April 2 that it would release the world's first plasma treatment for COVID-19 in the second half of this year.The company said the "GC5131A," a COVID-19 treatment it is developing, can be commercialized within this year.The GC5131A is a hyperimmune globulin made with immun
Bukwang Pharmaceutical has signed a partnership agreement with the new drug development unit (DDU) of University of Dundee of the United Kingdom to develop a new Parkinson's disease treatment.The contract is the same as the DDU's drug discovery partnerships with global pharmaceutical compani
A Korea-Japan war seems inevitable in the Korean market for next-generation gastroesophageal reflux disease treatments as Takeda Pharmaceutical, Japan's No. 1 drug maker, is launching its new drug TAKECAB in Korea next month to compete with CJ Healthcare’s K-CAB.Industry watchers said on Feb. 20
After Japan’s Takeda Pharmaceutical Co. has jumped up to be the world’s eighth largest global pharmaceutical company through a bold merger and acquisition (M&A) strategy, there are growing calls for domestic pharmaceutical firms to consider an aggressive M&A strategy to become truly global companies
Samsung Electronics will sponsor the Olympic Games as a worldwide partner for eight more years until the end of 2028.Samsung Electronics announced on Dec. 4 that it has extended its official Olympic sponsorship contract to 2028 with the International Olympic Committee (IOC).Ko Dong-jin, CEO and pres
Samyang Biopharm announced on July 23 that it is planning to establish an overseas subsidiary in Boston next month to strengthen its bio business.The US subsidiary will develop and introduce candidate biomaterials and related technologies at an early stage based on the networking with global compani
Orphan drugs, which refer to drugs developed to treat rare diseases, are emerging as a new battlefield for global pharmaceutical companies. They have been neglected by the industry because the number of rare disease patients is small and it is hard to carry out clinical trials. However, orphan drugs
The Korean biotech industry joined competition to develop a chimeric antigen receptor-T cell (CAR-T) therapeutic drug called “the cancer drug of doctors’ dream.” CAR-T is a technology that allows T cells which are a kind of common immune cells in blood to selectively attack cancer cells after pinpoi
Samsung Bioepis Co., a biopharmaceutical affiliate of Samsung, announced on August 21 it has entered into a strategic collaboration agreement with Japan's Takeda Pharmaceutical Co., the largest pharmaceutical company in Asia, to jointly develop novel biologic drugs.The latest agreement is to create